Evaluating the Psychometric Properties of the Simplified Chinese Version of PROMIS-29 in Patients with Hematologic Malignancies

Abstract

Abstract Background The patient-reported outcomes measurement information system 29-item profile (PROMIS-29) is a widely utilized self-reported instrument for assessing health outcomes from the patients’ perspectives. This study aimed to evaluate the psychometric properties of the PROMIS-29 Chinese version among patients with hematological malignancy. Methods Conducted as a cross-sectional, this research was approved by the Medical Ethical Committee of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (registration number QTJC2022002-EC-1). We employed convenience sampling to enroll eligible patients with hematological malignancy from four tertiary hospitals in Tianjin, Shandong, Jiangsu, and Anhui province in China between June and August 2023. Participants were asked to complete a socio-demographic information questionnaire, the PROMIS-29, and the Functional Assessment of Cancer Therapy-General (FACT-G). We assessed the reliability, ceiling and floor effects, structural, convergent discriminant and criterion validity of the PROMIS-29 profile. Results A total of 354 patients with a mean age of 46.93 years was included in the final analysis. The reliability of the PROMIS-29 was affirmed, with Cronbach’s α for the domains ranging from 0.787 to 0.968. Some domains exhibited floor and ceiling effects. Criterion validity was supported by significant correlations between the PROMIS-29 and FACT-G scores, as determined by the Spearman correlation test(P＜0.01). Confirmatory factor analysis (CFA) indicated a good model fit, with indices of χ2/df (2.602), IFI (0.960) ,and RMSEA (0.067). The Average Variance Extracted (AVE) values for the seven dimensions of PROMIS-29, ranging from 0.500 to 0.910, demonstrated satisfactory convergent validity. Discriminant validity was confirmed by ideal √AVE values. Conclusion The Chinese version of the PROMIS-29 profile has been validated as an effective instrument for assessing symptoms and functions in patients with hematological malignancy, underscoring its reliability and applicability in this specific patient group.